Ductal carcinoma in situ (DCIS) of the breast--a therapeutic dilemma.
The incidence of ductal carcinoma in situ of the breast (DCIS) is low. Multifocality and difficulties in defining the extent of the disease are the main problems in relation to the therapy. Biologic characterization still is incomplete. Ablative treatment gives a 100% cure. Prospective trials are needed to evaluate breast conserving therapy.